HolderBook

SECTOR GAMMA AS

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1475373
Reported value
$461.0M
Positions
40
Top 10 weight
48.4%
Filed
2026-08-12
Days after quarter end
43

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
BRISTOL-MYERS SQUIBB COBMY$41.8M726,1159.08%-2.78pp31q-12.3%-$5.9M
MERCK & CO INCMRK$27.9M217,0086.05%-1.35pp5q-16.6%-$5.6M
MEDTRONIC PLCMDT$27.6M352,4375.98%+0.24pp25q+25.6%+$5.6M
PFIZER INCPFE$24.2M1,004,2155.25%-1.99pp11q-8.0%-$2.1M
INCYTE CORPINCY$19.4M170,7534.20%-0.26pp31q-14.8%-$3.4M
ELEVANCE HEALTH INC FORMERLYELV$17.2M44,4993.73%+0.69pp31q+1.2%+$207.7K
BIOMARIN PHARMACEUTICAL INCBMRN$16.9M294,9183.66%+0.46pp19q+22.9%+$3.1M
THERMO FISHER SCIENTIFIC INCTMO$16.8M33,5843.65%-newNEW
CVS HEALTH CORPCVS$16.1M155,3373.49%+1.19pp11q+14.8%+$2.1M
IQVIA HLDGS INCIQV$15.1M77,9443.27%+1.65pp2q+93.7%+$7.3M
IONIS PHARMACEUTICALS INCIONS$15.0M189,4683.26%+0.25pp31q+11.8%+$1.6M
BECTON DICKINSON & COBDX$14.1M93,1683.06%-0.01pp8q+12.8%+$1.6M
ABBOTT LABORATORIESABT$13.4M147,4442.90%+0.78pp2q+68.4%+$5.4M
GE HEALTHCARE TECHNOLOGIES IGEHC$13.3M207,8632.89%+0.76pp13q+64.4%+$5.2M
ZIMMER BIOMET HOLDINGS INCZBH$12.3M142,3072.66%-0.67pp18q-8.7%-$1.2M
BIOGEN INCBIIB$11.7M54,1632.54%-1.36pp31q-39.9%-$7.8M
QIAGEN NVQGEN$11.2M287,6402.44%+0.90pp2q+77.1%+$4.9M
CENTENE CORP DELCNC$10.4M162,4052.26%+1.01pp23qHELD
REGENERON PHARMACEUTICALSREGN$9.8M15,7802.13%-newNEW
BIO RAD LABS INCBIO$9.8M33,3502.12%+0.56pp11q+40.4%+$2.8M
CARDINAL HEALTH INCCAH$9.7M40,6892.10%-0.64pp31q-25.9%-$3.4M
AMGEN INCAMGN$9.5M26,2812.06%-1.85pp9q-44.3%-$7.6M
BRUKER CORPBRKR$9.2M152,3521.99%-0.18pp29q-40.0%-$6.1M
AVANTOR INCAVTR$9.0M906,0881.95%+0.66pp5q+30.3%+$2.1M
PTC THERAPEUTICS INCPTCT$8.2M100,0001.77%+0.56pp7q+33.3%+$2.0M
LABCORP HOLDINGS INCLH$7.3M26,0191.58%+0.38pp5q+36.8%+$2.0M
DEXCOM INCDXCM$6.9M102,1221.49%+0.66pp5q+82.0%+$3.1M
ASCENDIS PHARMA A/SASND$5.7M21,3051.23%-newNEW
EDWARDS LIFESCIENCES CORPEW$5.5M60,4021.19%+0.04pp15qHELD
SYNDAX PHARMACEUTICALS INCSNDX$5.3M241,7391.15%-0.43pp4q-15.5%-$967.7K
BOSTON SCIENTIFIC CORPBSX$5.2M121,1281.12%-newNEW
KURA ONCOLOGY INCKURA$4.8M433,0121.03%+0.24pp4q+5.1%+$232.6K
TRAVERE THERAPEUTICS INCTVTX$4.5M80,0000.99%-newNEW
CRINETICS PHARMACEUTICALS INCRNX$4.3M114,6280.93%+0.12pp3q+21.7%+$764.6K
TANDEM DIABETES CARE INCTNDM$4.0M267,0910.87%-0.33pp6qHELD
IOVANCE BIOTHERAPEUTICS INCIOVA$4.0M968,4660.87%+0.13pp2q+7.6%+$284.8K
CYTOKINETICS INCCYTK$3.8M45,0000.83%-newNEW
ORGANON & COOGN$3.7M270,7810.80%+0.26pp4q-28.0%-$1.4M
ARDELYX INCARDX$3.5M686,8440.76%+0.03pp2q+33.1%+$870.6K
INTELLIA THERAPEUTICS INCNTLA$3.1M185,1770.68%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 63.9%Medical Devices 19.3%Insurance 6.0%Healthcare Services 5.1%Instruments & Controls 3.7%Wholesale & Distribution 2.1%
 
SectorValueShare
Biotech & Pharma$294.7M63.9%
Medical Devices$88.8M19.3%
Insurance$27.6M6.0%
Healthcare Services$23.4M5.1%
Instruments & Controls$16.8M3.7%
Wholesale & Distribution$9.7M2.1%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+9.7%+14.8%-5.1%100%
Q1 2026-1.6%-4.6%+3.0%100%
Q4 2025+10.6%+2.4%+8.3%100%
Q3 2025+4.1%+7.8%-3.7%100%
Q2 2025-4.1%+10.5%-14.6%100%
Q1 2025+4.7%-4.6%+9.3%99%
Q4 2024-7.9%+2.1%-10.0%100%
Q3 2024+9.3%+5.4%+3.9%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$461.0M4071911948.4%43
Q1 2026$423.5M42111215554.1%37
Q4 2025$438.7M3632210855.7%43
Q3 2025$403.3M416296353.3%31
Q2 2025$305.9M3861217151.1%31
Q1 2025$312.2M3361511356.6%43
Q4 2024$290.9M304815361.2%42
Q3 2024$329.6M294158362.4%44
Q2 2024$267.7M282422261.8%40
Q1 2024$354.8M284915663.3%38
Q4 2023$412.1M306914458.0%36
Q3 2023$391.3M2821313365.4%37
Q2 2023$446.9M295159763.5%40
Q1 2023$412.5M3111713162.8%42
Q4 2022$437.4M317812760.2%39
Q3 2022$388.0M3111215766.6%40
Q2 2022$447.0M3731511659.9%36
Q1 2022$460.2M4091713255.7%36
Q4 2021$425.4M335522154.7%39
Q3 2021$501.3M29213131056.1%29
Q2 2021$564.6M378719452.7%35
Q1 2021$546.0M3361215255.4%40
Q4 2020$525.5M2941114356.7%41
Q3 2020$439.4M2821214659.9%40
Q2 2020$484.4M323821255.2%38
Q1 2020$469.0M3131116955.7%41
Q4 2019$624.4M3751715257.0%43
Q3 2019$591.8M343139359.8%36
Q2 2019$622.1M3441514360.0%31
Q1 2019$623.5M335819562.7%43
Q4 2018$594.7M33000060.6%43

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.